Kairos Pharma (KAPA) Cash & Equivalents (2023 - 2025)

Kairos Pharma (KAPA) has 3 years of Cash & Equivalents data on file, last reported at $4.5 million in Q4 2025.

• Quarterly Cash & Equivalents rose 253.07% year-over-year to $4.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.5 million (up 253.07% YoY) and the FY2025 annual result came in at $4.5 million, up 253.07% from the prior year.
• Cash & Equivalents grew to $4.5 million in Q4 2025, from $3.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $4.5 million in Q4 2025 to a low of $3504.0 in Q1 2025.
• A 3-year average of $1.7 million and a median of $1.3 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents soared 3149.49% — and 2025, when it surged 253.07%.
• Tracing KAPA's Cash & Equivalents over 3 years: stood at $93000.0 in 2023, then jumped by 1267.74% to $1.3 million in 2024, then surged by 253.07% to $4.5 million in 2025.
• The last three Cash & Equivalents figures came in at $4.5 million (Q4 2025), $3.0 million (Q2 2025), and $3504.0 (Q1 2025), per Business Quant data.